- Email: [email protected]
Preliminary results of weekly chemotherapy with paclitaxel (T) and carboplatin (CBP) in patients (P) with advanced lung cancer (ALC)
s54
Abstracts
14/20 OR (70%, 95% CI: SO%-90%) and 6/20 NC (30%). After treatment three pts (stage IIIA) underwent successful radical resection. A median of three (3-6) cycles were administered. WHO grade 3 and 4 toxicity was neutropenia in 4% and l%, thrombocytopenia in 2% and l%, nausea and vomiting in 1% and O%, respectively. Two pts developed grade 3 anemia and one pt was admitted for febrile neutropenia. Median survival (Kaplan-Meier) was 52 weeks (95% CI: 33-71), and median time to progression was 34 weeks (95% CI: 29-39). After 22 and 52 weeks of surgery both pathological CR pts are free of disease. Mean dose intensity was (mg/m*/week): CP 18.75/GZ 610. Conclusion: These preliminary findings suggest that the combination of CP/GZ has promising activity in locally advanced and metastatic NSCLC with modest toxicity. The inverse sequence of administration with respect to the classic does not seem to affect the results. Cisplatin-etoposide versus cisplatin-epirubicin for small cell lung cancer Kocit* D, RaduloviC* * S. * Clinic of lung diseases and TB, NG, Yugoslavia; Yugoslavia.
T * Institute
of Oncology
and
Radiology,
Belgrade,
In a randomized clinical study 50 patients (43 males and seven females) with small cell lung cancer (15 patients with limited-stage disease and 28 patients with extensive stage disease) were involved. They were treated in the Instiute of Oncology and Radiology. They were randomized in two groups: -
group A - received cisplatin 60 mg/m* day 1, etoposide 120 mg/m* day I, 3, 5; group B - received cisplatin 60 mg/m2 day 1, epirubicin 120 mg/m’ day 2.
Treatment was repeated every 4 weeks. Patients were supposed to receive six cycles. A total of 43 patients were evaluable for response (25 in group A and 18 in group B). In group A we had overall response rate (RR) 7/25 (28%) patients; complete response (CR) l/25 (4%) and partial response (PR) 6/25 (24%). In the same group we had non-response (NonRR) 18/25 patients (72%); 12/25 (48%) with stable disease (SD), and 5/25 (20%) with progressive disease (PD) and l/25 (4%) exitus. In group B we had RR - 13/18 patients (72.2%); CR - 3/18 (16.7%), and PR - lo/18 (55.5%). Non-RR 5/18 patients (27.8%); SD - 3/18 (16.7%), and PD - 2/18 (11.1%). Difference in RR between these two groups is statistically significant ( x2 = 8.03; P < 0.01). A phase II trial of vinorelbine and cisplatin in previously intreated inoperable non-small cell lung cancer Shih’* JF, Pemg’ RP, Chen’ YM, Chou’ KC, PW’ JK, Burillon* JP, Ducrocq* M, Delgado* FM. Chest Dept. / VGHTaipei,
Taiwan’.
Institut
de Recherche
Pierre Fabre,
France’.
f’urpose: A phase II trial was conducted to evaluate the efficacy and toxicity of the combination of vinorelbine and cisplatin in patients with previously untreated, inoperable (IlIB/IV) NSCLC. Patients and Methods: From April 1996 to
May 1997, 52 patients were enrolled for study, 50 patients are eligible and evaluable for both response and toxicity assessment. Therapy consisted of vinorelbine 30 mg/m’ on days 1,5 and cisplatin 80 mg/m* on day 1 every 3 weeks. Results: A total of 211 treatment courses were administered, the median number of cycles administered per patient was 4.5 (range l-61, the median dose intensity for vinorelbine was 16.9 mg/m’/week (84.4%), whilst that of cisplatin was 22.8 mg/m*/week (84.7%). tienty-five patients responded to therapy for an overall response rate of 50% (CR 2%, PR 48%). The main toxicities were vomiting, myelosuppression and diarrhea. WHO grade 3/4 nausea/vomiting 58%, anemia 41%, neutropenia 12% and diarrhea 14%. The median time to progression was 7.9 months (range 0.4-13 months). The median survival was 13 months, and 54% of patients were alive at 1 year. Conclusion: The combination of vinorelbine and cisplatin achieves a high response with acceptable toxicity profile in patients with advanced NSCLC, and a 54% survival at 1 year. Preliminary results of weekly chemotherapy with paclitaxel (T) and carboplatin (CBP) in patients (PI with advanced lung cancer (ALC) Schneider C-P, Kath R, Hiiflken K. Klinik und Poliklinikfir Innere Medizin II Hiimatologie / Onkologie / Endokrinologie/ Stofiechsel der Friedrich-Schiller-Universitijt Jena, Erlanger Allee 101, 07740 Jena. Objectives: Evaluation of feasibility, efficacy and toxicity of weekly T/CBP in patients (P) with ALC. Methods: 21 P
(median age 60 years, median WHO-performance status 1) with ALC (19 non-small-cell, two small-cell) received 100 mg/m* T over 1 or 3 h (with concomitant medication) and CBP target AUC = 2 or 3 over 30 min on day 1, 8, 15, 22,29, 36. Treatment was repeated on day 50. Eleven P were pretreated, eight of them with platinum compounds and two with anthracyclines. Evaluation of response and toxicity was performed before each subsequent course. Results: 20 P were evaluable for response (1 CR, 6 PR; 4 NC and 9 PD), with five early deaths because of rapid disease progression, but none of them treatment related. Seventeen P were evaluable for toxicity (three WHO-grade 3/4 hematotoxicity). Two severe allergic reactions were withdrawal criteria in both patients. Neuropathy was the most common non-hematologic toxicity, not exceeding WHO-grade 2. Conclusion: Weekly chemotherapy with T and CBP is feasible and effective, especially in platinum naive P with ALC. Although dose density is higher than in the standard schedule with 175 mg/m* T and CBP target AUC = 6 every 3 weeks toxicity was mild. Thus, T/CBP is especially applicable in an outpatient palliative setting. Neoadjuvant therapy in locoregionally advanced non-small cell lung cancer (NSCLC) in the course of 7 years Spelda S, Skrickova J, Kaplanova J. Dept. of TB and Respir. Dis. and Palliative public.
Care
Unit, Babice
nad Svitavoy
Czech Re-
The approach to apply neoadjuvant treatment should improve the therapeutic outcomes of patients (pts) with locore-
Abstracts
14/20 OR (70%, 95% CI: SO%-90%) and 6/20 NC (30%). After treatment three pts (stage IIIA) underwent successful radical resection. A median of three (3-6) cycles were administered. WHO grade 3 and 4 toxicity was neutropenia in 4% and l%, thrombocytopenia in 2% and l%, nausea and vomiting in 1% and O%, respectively. Two pts developed grade 3 anemia and one pt was admitted for febrile neutropenia. Median survival (Kaplan-Meier) was 52 weeks (95% CI: 33-71), and median time to progression was 34 weeks (95% CI: 29-39). After 22 and 52 weeks of surgery both pathological CR pts are free of disease. Mean dose intensity was (mg/m*/week): CP 18.75/GZ 610. Conclusion: These preliminary findings suggest that the combination of CP/GZ has promising activity in locally advanced and metastatic NSCLC with modest toxicity. The inverse sequence of administration with respect to the classic does not seem to affect the results. Cisplatin-etoposide versus cisplatin-epirubicin for small cell lung cancer Kocit* D, RaduloviC* * S. * Clinic of lung diseases and TB, NG, Yugoslavia; Yugoslavia.
T * Institute
of Oncology
and
Radiology,
Belgrade,
In a randomized clinical study 50 patients (43 males and seven females) with small cell lung cancer (15 patients with limited-stage disease and 28 patients with extensive stage disease) were involved. They were treated in the Instiute of Oncology and Radiology. They were randomized in two groups: -
group A - received cisplatin 60 mg/m* day 1, etoposide 120 mg/m* day I, 3, 5; group B - received cisplatin 60 mg/m2 day 1, epirubicin 120 mg/m’ day 2.
Treatment was repeated every 4 weeks. Patients were supposed to receive six cycles. A total of 43 patients were evaluable for response (25 in group A and 18 in group B). In group A we had overall response rate (RR) 7/25 (28%) patients; complete response (CR) l/25 (4%) and partial response (PR) 6/25 (24%). In the same group we had non-response (NonRR) 18/25 patients (72%); 12/25 (48%) with stable disease (SD), and 5/25 (20%) with progressive disease (PD) and l/25 (4%) exitus. In group B we had RR - 13/18 patients (72.2%); CR - 3/18 (16.7%), and PR - lo/18 (55.5%). Non-RR 5/18 patients (27.8%); SD - 3/18 (16.7%), and PD - 2/18 (11.1%). Difference in RR between these two groups is statistically significant ( x2 = 8.03; P < 0.01). A phase II trial of vinorelbine and cisplatin in previously intreated inoperable non-small cell lung cancer Shih’* JF, Pemg’ RP, Chen’ YM, Chou’ KC, PW’ JK, Burillon* JP, Ducrocq* M, Delgado* FM. Chest Dept. / VGHTaipei,
Taiwan’.
Institut
de Recherche
Pierre Fabre,
France’.
f’urpose: A phase II trial was conducted to evaluate the efficacy and toxicity of the combination of vinorelbine and cisplatin in patients with previously untreated, inoperable (IlIB/IV) NSCLC. Patients and Methods: From April 1996 to
May 1997, 52 patients were enrolled for study, 50 patients are eligible and evaluable for both response and toxicity assessment. Therapy consisted of vinorelbine 30 mg/m’ on days 1,5 and cisplatin 80 mg/m* on day 1 every 3 weeks. Results: A total of 211 treatment courses were administered, the median number of cycles administered per patient was 4.5 (range l-61, the median dose intensity for vinorelbine was 16.9 mg/m’/week (84.4%), whilst that of cisplatin was 22.8 mg/m*/week (84.7%). tienty-five patients responded to therapy for an overall response rate of 50% (CR 2%, PR 48%). The main toxicities were vomiting, myelosuppression and diarrhea. WHO grade 3/4 nausea/vomiting 58%, anemia 41%, neutropenia 12% and diarrhea 14%. The median time to progression was 7.9 months (range 0.4-13 months). The median survival was 13 months, and 54% of patients were alive at 1 year. Conclusion: The combination of vinorelbine and cisplatin achieves a high response with acceptable toxicity profile in patients with advanced NSCLC, and a 54% survival at 1 year. Preliminary results of weekly chemotherapy with paclitaxel (T) and carboplatin (CBP) in patients (PI with advanced lung cancer (ALC) Schneider C-P, Kath R, Hiiflken K. Klinik und Poliklinikfir Innere Medizin II Hiimatologie / Onkologie / Endokrinologie/ Stofiechsel der Friedrich-Schiller-Universitijt Jena, Erlanger Allee 101, 07740 Jena. Objectives: Evaluation of feasibility, efficacy and toxicity of weekly T/CBP in patients (P) with ALC. Methods: 21 P
(median age 60 years, median WHO-performance status 1) with ALC (19 non-small-cell, two small-cell) received 100 mg/m* T over 1 or 3 h (with concomitant medication) and CBP target AUC = 2 or 3 over 30 min on day 1, 8, 15, 22,29, 36. Treatment was repeated on day 50. Eleven P were pretreated, eight of them with platinum compounds and two with anthracyclines. Evaluation of response and toxicity was performed before each subsequent course. Results: 20 P were evaluable for response (1 CR, 6 PR; 4 NC and 9 PD), with five early deaths because of rapid disease progression, but none of them treatment related. Seventeen P were evaluable for toxicity (three WHO-grade 3/4 hematotoxicity). Two severe allergic reactions were withdrawal criteria in both patients. Neuropathy was the most common non-hematologic toxicity, not exceeding WHO-grade 2. Conclusion: Weekly chemotherapy with T and CBP is feasible and effective, especially in platinum naive P with ALC. Although dose density is higher than in the standard schedule with 175 mg/m* T and CBP target AUC = 6 every 3 weeks toxicity was mild. Thus, T/CBP is especially applicable in an outpatient palliative setting. Neoadjuvant therapy in locoregionally advanced non-small cell lung cancer (NSCLC) in the course of 7 years Spelda S, Skrickova J, Kaplanova J. Dept. of TB and Respir. Dis. and Palliative public.
Care
Unit, Babice
nad Svitavoy
Czech Re-
The approach to apply neoadjuvant treatment should improve the therapeutic outcomes of patients (pts) with locore-